Table 1.
Demographics of women with mesh complications by exposure or pain in the absence of exposure.
| Pain (n = 15) | Exposure (n = 15) | P value | |
|---|---|---|---|
|
| |||
| Age (y) | 56 (42–59) | 56 (54–68) | 0.23 |
| BMI (kg/m2) | 28.0 (25.1–32.2) | 30.0 (24.7–32.4) | 0.80 |
| Median parity (range) | 3 (2–5) | 3 (1–5) | 0.90 |
| Midurethral sling | 10 (66.7%) | 7 (46.7%) | 0.46 |
| Prolapse mesh | 5 (33.3%) | 8 (53.3%) | 0.46 |
| Duration implantation (mo) | 36.6 (15–56) | 58.5 (22–73) | 0.57 |
| Postmenopausal | 11 (73.3%) | 13 (86.7%) | 0.65 |
| Hormone therapy use* | 8 (53.3%) | 8 (53.3%) | 0.99 |
| Prior hysterectomy | 11 (73.3%) | 9 (60.0%) | 0.70 |
| Current or smoking history^ | 8 (53.3%) | 8 (53.3%) | 0.99 |
| Diabetes | 3 (20.0%) | 1 (6.7%) | 0.60 |
| Chronic steroid use | 0 (0%) | 1 (6.7%) | 0.99 |
| Baseline VAS Pelvic Pain | 30.5 (23–47) | 73 (45–95) | 0.046 |
| TGF-β1 (pg/μg protein)° | 11.8 (8.2–14.4) | 9.1 (6.9–13.3) | 0.83 |
| bFGF (pg/μg protein)+ | 6.5 (4.6–7.6) | 6.5 (4.0–10.4) | 0.99 |
| PDGF-BB (pg/μg protein)‡ | 0.4 (0.3–0.5) | 0.6 (0.4–0.7) | 0.18 |
| MCP-1 (pg/μg protein)‡ | 2.8 (1.6–3.0) | 2.1 (1.7–2.5) | 0.63 |
| IGFBP-1 (pg/μg protein)‡ | 14.2 (11.9–38.6) | 24.6 (20.2–31.6) | 0.29 |
Median (interquartile range) is listed for continuous variables, frequencies (%) for categorical variables. P values represent Mann–Whitney U for continuous variables and or Fishers Exact for categorical variables. VAS indicates visual analog scale.
*
includes vaginal estrogen.
^
smoking information missing on one patient.
°
TGF-β1 samples include 8 patients with pain and 8 with exposure.
+
FGF analysis included 7 patients with pain and 11 with exposure.
‡
Luminex analysis included 9 patients with pain and 8 with exposure complications (see Fig. 1).